Healthcare provider profile · identity verified

Christopher Scott Montjoy, MD

Internal Medicine · GREENVILLE, SC · NPI 1407899081

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	360	35
Eliquis	Apixaban	313	23
Omeprazole	Omeprazole	246	26
Gabapentin	Gabapentin	225	20
Metoprolol Tartrate	Metoprolol Tartrate	219	25
Potassium Chloride	Potassium Chloride	203	17
Donepezil Hcl	Donepezil Hcl	201	20
Escitalopram Oxalate	Escitalopram Oxalate	193	25
Xarelto	Rivaroxaban	178	suppressed
Amlodipine Besylate	Amlodipine Besylate	173	20
Memantine Hcl	Memantine Hcl	167	16
Losartan Potassium	Losartan Potassium	156	13
Atorvastatin Calcium	Atorvastatin Calcium	154	17
Tamsulosin Hcl	Tamsulosin Hcl	145	16
Lisinopril	Lisinopril	132	16
Trazodone Hcl	Trazodone Hcl	127	27
Furosemide	Furosemide	110	20
Carbidopa-Levodopa	Carbidopa/Levodopa	105	11
Mirtazapine	Mirtazapine	100	14
Carvedilol	Carvedilol	90	suppressed
Montelukast Sodium	Montelukast Sodium	87	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	87	14
Jardiance	Empagliflozin	78	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	74	suppressed
Divalproex Sodium	Divalproex Sodium	68	11
Nuplazid	Pimavanserin Tartrate	64	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	59	11
Baclofen	Baclofen	55	suppressed
Methenamine Hippurate	Methenamine Hippurate	55	suppressed
Memantine Hcl Er	Memantine Hcl	52	suppressed
Myrbetriq	Mirabegron	51	suppressed
Clopidogrel	Clopidogrel Bisulfate	48	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	48	suppressed
Metoprolol Succinate	Metoprolol Succinate	47	suppressed
Januvia	Sitagliptin Phosphate	46	suppressed
Hydralazine Hcl	Hydralazine Hcl	43	suppressed
Olanzapine	Olanzapine	43	suppressed
Famotidine	Famotidine	41	suppressed
Gemtesa	Vibegron	41	suppressed
Atenolol	Atenolol	39	suppressed
Pravastatin Sodium	Pravastatin Sodium	39	suppressed
Allopurinol	Allopurinol	38	suppressed
Lorazepam	Lorazepam	36	21
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	35	18
Levetiracetam	Levetiracetam	35	suppressed
Finasteride	Finasteride	34	suppressed
Tramadol Hcl	Tramadol Hcl	31	16
Prednisone	Prednisone	30	11
Sertraline Hcl	Sertraline Hcl	30	suppressed
Tizanidine Hcl	Tizanidine Hcl	29	suppressed
Rivastigmine	Rivastigmine	28	suppressed
Paroxetine Hcl	Paroxetine Hcl	27	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	26	suppressed
Bumetanide	Bumetanide	25	suppressed
Diltiazem 24hr Er	Diltiazem Hcl	25	suppressed
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	24	suppressed
Citalopram Hbr	Citalopram Hydrobromide	24	suppressed
Fluticasone Propionate	Fluticasone Propionate	24	14
Hydrochlorothiazide	Hydrochlorothiazide	24	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	24	suppressed
Metformin Hcl Er	Metformin Hcl	23	suppressed
Benztropine Mesylate	Benztropine Mesylate	22	suppressed
Cephalexin	Cephalexin	22	20
Duloxetine Hcl	Duloxetine Hcl	22	suppressed
Metformin Hcl	Metformin Hcl	22	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	22	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	22	11
Carbidopa-Levodopa Er	Carbidopa/Levodopa	21	suppressed
Olanzapine Odt	Olanzapine	21	suppressed
Propranolol Hcl	Propranolol Hcl	21	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	21	suppressed
Benazepril Hcl	Benazepril Hcl	20	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	20	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	20	suppressed
Desloratadine	Desloratadine	19	suppressed
Fenofibrate	Fenofibrate	19	suppressed
Isosorbide Mononitrate	Isosorbide Mononitrate	19	suppressed
Oxycodone Hcl	Oxycodone Hcl	19	suppressed
Raloxifene Hcl	Raloxifene Hcl	19	suppressed
Restasis	Cyclosporine	19	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	19	14
Topiramate	Topiramate	19	suppressed
Gemfibrozil	Gemfibrozil	18	suppressed
Ondansetron Hcl	Ondansetron Hcl	18	11
Ropinirole Hcl	Ropinirole Hcl	18	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	17	suppressed
Fludrocortisone Acetate	Fludrocortisone Acetate	17	suppressed
Fluorometholone	Fluorometholone	17	suppressed
Methimazole	Methimazole	17	suppressed
Morphine Sulfate	Morphine Sulfate	17	17
Valacyclovir	Valacyclovir Hcl	17	suppressed
Zonisamide	Zonisamide	17	suppressed
Latanoprost	Latanoprost	16	suppressed
Spiriva Respimat	Tiotropium Bromide	16	suppressed
Torsemide	Torsemide	16	suppressed
Azithromycin	Azithromycin	15	14
Estradiol	Estradiol	15	suppressed
Bupropion Hcl Sr	Bupropion Hcl	14	suppressed
Buspirone Hcl	Buspirone Hcl	14	suppressed
Carbamazepine Er	Carbamazepine	14	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	14	suppressed
Digoxin	Digoxin	14	suppressed
Roflumilast	Roflumilast	14	suppressed
Verapamil Hcl	Verapamil Hcl	14	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	13	suppressed
Haloperidol	Haloperidol	13	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	13	suppressed
Metronidazole	Metronidazole	13	suppressed
Movantik	Naloxegol Oxalate	13	suppressed
Lithium Carbonate	Lithium Carbonate	12	suppressed
Nyamyc	Nystatin	12	suppressed
Risperdal Consta	Risperidone Microspheres	12	suppressed
Solifenacin Succinate	Solifenacin Succinate	12	suppressed
Spironolactone	Spironolactone	12	suppressed
Budesonide	Budesonide	11	suppressed
Fluconazole	Fluconazole	11	suppressed
Levofloxacin	Levofloxacin	11	suppressed
Meloxicam	Meloxicam	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error